Work

MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps7566

Authors: Alexander M. Lesokhin, Jonathan L. Kaufman, Ashraf Badros, Jorge Acosta, Patrick Muller, Carolyn Lou, Ashleigh O'Connell, Gabriel Afram, Attaya Suvannasankha

Institutions: Memorial Sloan Kettering Cancer Center, Emory University, Winship Cancer Institute, University of Maryland, Baltimore, Bristol-Myers Squibb (Switzerland), Pfizer (United States), Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4410812394

FWCI:

Cites:

Cited by:

Related to: 10